Puma Biotechnology, Inc. (NYSE: PBYI) announced that interim results from a Phase II clinical trial of Puma's investigational drug PB272 (neratinib) ...
News
- Puma Biotech (PBYI) Announces Encouraging Interim Data from PB272 Phase 2 Control Trial in ...
- Puma Biotech (PBYI) Updates on PB272 NSABP FB-7 Phase 2; No Significant Difference Noted
Puma Biotechnology, Inc. (NYSE: PBYI) announced that a biomarker ... 2016 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) that is ...
- Texas Innovations in Health Care: More Austin biotech companies go public, but hit stock turbulence
Editor's Note: This article is part of a special series produced jointly by the Business Journals in Austin, Dallas, Houston and San Antonio, highlighting ...
- This Booming Tea Seller Has 3 Business-Building Lessons to Share
So he and his roommate, Rickey Ishida (who happened to be a biomedical engineer), began experimenting with high-caffeine tea blends to get ...
- Puma Biotechnology, Inc. (NYSE:PBYI) update interim results from Phase II clinical trial of PB272 ...
Puma Biotechnology, Inc. (NYSE:PBYI) announced that updated interim ... Symposium (SABCS) that is currently taking place in San Antonio, Texas.